CLL Lab Tests Revealed
Navigating Care with Confidence
For many living with CLL, lab tests are a constant part of the experience, but understanding what they mean isn’t always easy. In this in-depth conversation, CLL expert Dr. Adam Kittai joins longtime patient advocate Michele Nadeem-Baker to explore how blood tests guide real-world care decisions.
From identifying when “watch and wait” should shift to active treatment, to interpreting genetic markers like IGHV and TP53, to understanding MRD testing and remission, this discussion helps demystify what’s behind the numbers and how they shape your care.
Program Topics
How ongoing blood tests guide CLL monitoring and treatment timing
What genetic tests like IGHV, TP53, and FISH reveal about your prognosis
How MRD (minimal residual disease) testing is used to assess remission
Differences in follow-up for time-limited vs. continuous treatment
Questions to ask about your labs—and what they mean for your future care
Program Panel
Program Partner
Thank you to Blood Cancer United for their partnership. They are here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.
This is not medical advice. Please consult with your healthcare provider to make informed treatment decisions.
This interview has been edited for clarity and length. The views and opinions expressed in this interview do not necessarily reflect those of The Patient Story. This content does not replace professional medical advice.
Hear from people living with chronic lymphocytic leukemia (CLL)
Real experiences with diagnosis, treatment choices, side effects, and life beyond CLL — in their own words.
